1. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients 
Sarah Berhane, Hidenori Toyoda, Toshifumi Tada, Takashi Kumada, Chiaki Kagebayashi, Shinji Satomura, Nora Schweitzer, Arndt Vogel, Michael P. Manns, Julia Benckert, Thomas Berg, Maria Ebker, Jan Best, Alexander Dechêne, Guido Gerken, Joerg F. Schlaak, Arndt Weinmann, Marcus A. Wörns, Peter Galle, Winnie Yeo, Frankie Mo, Stephen L. Chan, Helen Reeves, Trevor Cox, Philip Johnson 
Clinical Gastroenterology and Hepatology 
Volume 14, Issue 6, Pages e6 (June 2016)
DOI: /j.cgh
Copyright © 2016 AGA Institute Terms and Conditions

2. Figure 1
ROC curves comparing the overall performance of the GALAD model with the individual biomarkers in the (A) UK, (B) Japan, and (C) German cohorts, as well as in early stage HCC (within Milan criteria) in the (D) UK and (E) Japan cohorts.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

3. Figure 2
ROC curves comparing the performance of the GALAD model in subgroups of patients with unifocal tumors of different sizes in the (A) UK, (B) Japan, and (C) Germany cohorts, in addition to those within Milan criteria in the (D) UK and (E) Japan cohorts.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

4. Figure 3
Survival according to BALAD-2 score in the (A) UK, (B) Japan, (C) German, and (D) Hong Kong data sets. (E) Table shows the median survival in each cohort according to the BALAD-2 score.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

5. Supplementary Figure 1
ROC curves showing (A) the performance of the GALAD model on the Japanese and German cohorts in comparison with the United Kingdom; and the ability of the GALAD model to classify HCC correctly from (B) pancreatic adenocarcinoma/cholangiocarcinoma and (C) healthy controls within the UK cohort.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

6. Supplementary Figure 2
ROC curves showing the ability of the GALAD model to classify HCC correctly from (A) pancreatic adenocarcinoma, (B) extrahepatic cholangiocarcinoma, and (C) intrahepatic cholangiocarcinoma in the UK cohort.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

7. Supplementary Figure 3
ROC curves showing the performance of the GALAD model in the different etiologies (HCV, HBV, alcohol, and other) of (A) UK, (B) Japan, (C) Germany, and (D) Europe (UK and Germany combined).
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

8. Supplementary Figure 4
ROC curves showing the performance of the GALAD model in Japanese HCV and HBV patients according to (A) their SVR status and (B) active treatment, respectively.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

9. Supplementary Figure 5
Survival according to BALAD-2 score in the (A) UK, (B) Japan, (C) German, and (D) Hong Kong data sets, in patients followed up for a minimum of 18 months. (E) The table shows the corresponding median survival in each cohort according to the BALAD-2 score.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

10. Supplementary Figure 6
Survival in Europe (UK and Germany) according to the (A) ALBI grade and the (B) BALAD-2 score. (C) The table shows the corresponding median survival in months at each score/grade.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

11. Supplementary Figure 7
Survival according to the BALAD-2 score in Japanese patients undergoing (A) curative, (B) intermediate, and (C) palliative treatments. (D–F) The corresponding graphs for Europe (UK and Germany) are shown. (G) The table shows the median survival in each treatment group according to the BALAD-2 score.
Clinical Gastroenterology and Hepatology  , e6DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions